The authors claimed that once (participants were) in withdrawal, most of the weight lost was regained within one year (4)
Conclusions The current study revealed that semaglutide, as an adjunct to AID in T1D patients, particularly in those with higher BMI, caused greater weight loss and higher glycemic benefits
Tirzepatide enhances insulin secretion in a glucose-dependent manner, suppresses inappropriate glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways
Licensed compounding pharmacy sourcing Compounded medications are sourced from licensed compounding pharmacies
Nothing (including side effects!) has disrupted my life more than the monthly hunt I go on for Ozempic
Further large-scale randomized controlled trials are warranted to confirm this study's findings